We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Johnson & Johnson (J&J) has disclosed that three of its subsidiaries have received three separate subpoenas from the Boston, San Francisco and Philadelphia U.S. attorneys’ offices relating to marketing practices for Risperdal, Topamax and Natrecor.